Important New Product Launched by Sanofi

The U.S. FDA has approved Sanofi’s Qfitlia (fitusiran), the first antithrombin-lowering therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (age 12 years or older) with hemophilia A or B with or without factor VIII or IX inhibitors. Qfitlia is the first therapy approved in the U.S. for the treatment of hemophilia A or B with or without inhibitors. Qfitlia is administered subcutaneously starting once every two months using a prefilled pen or a vial plus syringe. Read more here..

Source: LA Kelley Communications, Inc.